-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AAHtethkCySLLihZ04ocFSYbIR27fmyi9R1H0adRvT0JVoLBicNs3j9vHmTypDx8 klI8PvVStE2RvKWv55ztlA== 0000891836-04-000398.txt : 20041112 0000891836-04-000398.hdr.sgml : 20041111 20041112162610 ACCESSION NUMBER: 0000891836-04-000398 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040930 FILED AS OF DATE: 20041112 DATE AS OF CHANGE: 20041112 EFFECTIVENESS DATE: 20041112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 041139690 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 sc0186.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for the Calendar Year or Quarter Ended: September 30, 2004 Check here if Amendment [ ]; Amendment Number: _________ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. November 10, 2004 - ------------------------- -------------------------- --------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [x] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 41 ----------- Form 13F Information Table Entry Value: 249,763 ----------- (thousands) List of Other Included Managers: None
Form 13F Information Table Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 Column 8 -------- -------- -------- -------- -------- -------- -------- -------- Title of Value Shrs or Sh/ Put/ Investment Other Voting Authority Name of Issuer Class Cusip (x$1000) Prn Amt Prn Call Discretion Managers Sole Shared None -------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Aclara Biosciences Inc. COM 00461P106 91 23,199 SH SOLE 23,199 Adolor Corp. COM 00724X102 2,603 231,414 SH SOLE 231,414 Alexion Pharmaceuticals Inc. COM 015351109 6,659 369,938 SH SOLE 369,938 Alkermes Inc. COM 01642T108 1,824 158,059 SH SOLE 158,059 Amgen Inc. COM 031162100 10,507 184,954 SH SOLE 184,954 Amylin Pharmaceuticals Inc. COM 032346108 19,555 952,982 SH SOLE 952,982 Array Biopharma Inc. COM 04269X105 164 23,474 SH SOLE 23,474 Atherogenics Inc. COM 047439104 7,688 233,325 SH SOLE 233,325 Barrier Therapeutics Inc. COM 06850R108 7,300 600,302 SH SOLE 600,302 Cephalon Inc. COM 156708109 1,518 31,689 SH SOLE 31,689 Cytokinetics Inc. COM 23282W100 1,573 118,300 SH SOLE 118,300 Dynavax Technologies Corp. COM 268158102 322 59,100 SH SOLE 59,100 GTX Inc. Del COM 40052B108 2,284 195,900 SH SOLE 195,900 Human Genome Sciences Inc. COM 444903108 164 15,051 SH SOLE 15,051 Incyte Corp. COM 45337C102 29,025 3,014,070 SH SOLE 3,014,070 Insmed Inc. COM 457669208 82 48,900 SH SOLE 48,900 Intermune Inc. COM 45884X103 1,614 136,927 SH SOLE 136,927 Intrabiotics Pharmaceuticals COM 46116T506 3,730 932,476 SH SOLE 932,476 Ligand Pharmaceuticals Inc. CL B 53220K207 1,740 173,657 SH SOLE 173,657 Myogen Inc. COM 62856E104 9,725 1,200,589 SH SOLE 1,200,589 Myriad Genetics Inc. COM 62855J104 648 37,888 SH SOLE 37,888 Nastech Pharmaceutical Inc. COM 631728409 3,003 210,180 SH SOLE 210,180 Neurogen Corp. COM 64124E106 34,406 5,325,999 SH SOLE 5,325,999 Nitromed Inc. COM 654798503 6,818 286,000 SH SOLE 286,000 Onyx Pharmaceuticals Inc. COM 683399109 5,690 132,300 SH SOLE 132,300 Oscient Pharmaceuticals Corp. COM 68812R105 756 213,037 SH SOLE 213,037 Pharmacyclics Inc. COM 716933106 364 35,300 SH SOLE 35,300 Pozen Inc. COM 73941U102 685 78,400 SH SOLE 78,400 Praecis Pharmaceuticals Inc. COM 739421105 110 50,100 SH SOLE 50,100 Renovis Inc. COM 759885106 123 15,396 SH SOLE 15,396 Rigel Pharmaceuticals Inc. COM 766559603 205 8,101 SH SOLE 8,101 Seattle Genetics Inc. COM 812578102 1,512 230,166 SH SOLE 230,166 Senomyx Inc. COM 81724Q107 7,637 848,639 SH SOLE 848,639 Sequenom Inc. COM 817337108 383 403,543 SH SOLE 403,543 Transkaryotic Therapies Inc. COM 893735100 1,517 85,581 SH SOLE 85,581 Trimeris Inc. COM 896263100 54,216 3,602,369 SH SOLE 3,602,369 Vicuron Pharmaceuticals Inc. COM 926471103 182 12,400 SH SOLE 12,400 Virologic Inc. COM 92823R201 1,140 569,799 SH SOLE 569,799 Incyte Genomics Notes 5.5% 2/01/2007 CONV BONDS 45337CAC6 2,475 2,500,000 PRN SOLE 2,500,000 Regeneron Conv Notes 5.5% 10/17/08 (144A) CONV BONDS 75886FAA5 15,203 16,822,000 PRN SOLE 16,822,000 Regeneron Conv Notes 5.5% 10/17/08 CONV BONDS 75886FAB3 4,519 5,000,000 PRN SOLE 5,000,000
-----END PRIVACY-ENHANCED MESSAGE-----